Table 3.

Colon Cancer Stem Cells Targeted Therapies.

Sr. no	Name of the drug	Target	Preclinical/clinical	Reference
1.	Catumaxomab	CD133+/FpCAM+	Phase I-III in solid tumors. (NCT00836654)	48,49,52
2.	MT110	EpCAM	Phase I in solid tumors (NCT00635596)	50,51
3.	NCB-0846	TNIK	Preclinical	71
4.	OMP-131R10	Wnt pathway	Phase Ia/Ib (NCT02482441)	72
5.	ICG-001	Wnt pathway	Preclinical	133
6.	PRI-724	Wnt pathway	Phase I/II in solid tumors but withdrawn for Colon cancer. (NCT02413853)	134
7.	EGCG	Wnt pathway	Preclinical	135
8.	RO4929097	Notch pathway	Phase II (NCT01116687)	61
9.	OMP-21M18	Anti-DLL4 antibody	Phase I/Ib (NCT01189942)	136
10.	Honokiol	Notch pathway	Preclinical	59
11.	Cyclopamine	Hedgehog pathway	Preclinical	65
12.	GDC-0449	Hedgehog pathway	Preclinical Phase II (in combination with standard drug)	66 64
13.	LY2940002	PI3K/AKT pathway	Preclinical	137
14.	Polyethylenimine/miRNA145	miRNA 145	Preclinical	108,110
15.	Difluorinated curcumin	miRNA21, ABCG2	Preclinical	109,112,113
16.	Grape seed extract	Browning of adipocytes	Preclinical	115
17.	Acriflavine	HIF transcription inhibitor	Preclinical	138
18.	Salinomycin	ABC transporters	Preclinical	137,139,140
19.	Verteporfin	YAP	Preclinical	91,92
20.	OPCs	Hippo pathway	Preclinical	90